Skip to main content
. Author manuscript; available in PMC: 2025 Aug 25.
Published in final edited form as: Microbes Infect. 2023 Jul 8;25(8):105182. doi: 10.1016/j.micinf.2023.105182

Fig. 2. CD8+ immune T cells activated through antigen presentation of rGRA6Nt of T. gondii by human HLA-A2.1 molecule have the capability to remove tissue cysts of the parasite.

Fig. 2.

The HLA-A2.1-transgenic and WT mice were immunized intraperitoneally with 50 μg of rGRA6Nt twice (panel E) or three times (panels A-D) with 4-week intervals. Two weeks after the final immunization, CD8+ T cells were purified from their spleens and injected intravenously into infected HLA-2.1-NSG mice (2 × 106 cells/mouse) from a tail vein at 4 weeks after infection. An additional group of the HLA-A2.1-NSG mice did not receive any T cells as a control. These NSG mice were under treatment with sulfadiazine beginning at 5 days after infection to establish a chronic infection and maintain the parasite as the cysts until the end of the study. Seven days after the T cell transfer, the brains of the HLA-A2.1-NSG mice were applied for quantification of mRNA levels for bradyzoite (cyst)-specific BAG1 (A and E), CD8β (B), perforin (C), and GzmB (D) by real time RT-PCR. The results from three (panels A-D) or two (panel E) independent experiments are combined. Number of mice in each experimental group was 10–12 mice (panels A-D) and 7 or 8 mice (panel E). *P < 0.05, **P < 0.01, ***P < 0.001.